Müllerian inhibiting substance type II receptor (MISIIR): A novel, tissue-specific target expressed by gynecologic cancers

Jamie N Bakkum-Gamez, Giovanni Aletti, Kriste A. Lewis, Gary Keeney, Bijoy M. Thomas, Isabelle Navarro-Teulon, William Arthur Cliby

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Objective.: Müllerian inhibiting substance type II receptor (MISIIR) is expressed by ovarian, breast, and prostate cancers [Masiakos PT, et al. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) Type II Receptor, bind, and are responsive to MIS. Clin Cancer Res 1999;5:3488-99; Hoshiya Y, et al. Mullerian inhibiting substance promotes interferon {gamma}-induced gene expression and apoptosis in breast cancer cells. J Biol Chem 2003;278:51703-12; Hoshiya Y, et al. Mullerian inhibiting substance induces NFkB signaling in breast and prostate cancer cells. Mol. Cell. Endocrinol. 2003;211:43-9. [1-3]]. We investigated the expression patterns of MISIIR in benign and malignant gynecologic tissues and benign non-gynecologic tissues to better assess the relevance of MISIIR as a target for new therapeutic and diagnostic approaches to gynecologic cancers. Secondarily, we examined the impact of MISIIR expression on overall survival (OS) and disease-free survival (DFS) in a cohort of epithelial ovarian cancers (EOC). Methods.: Reverse-transcription polymerase chain reaction (RT-PCR), immunoblotting, and immunohistochemistry (IHC) were used to determine MISIIR expression. EOC cell lines (10), primary EOCs (12), and tissue microarrays (TMAs) containing benign gynecologic (179) and non-gynecologic tissues (25), EOC (182), endometrial carcinomas (109), uterine sarcomas (98), and ovarian dysgerminomas (22) were examined for MISIIR expression. Clinical data were collected for a cohort of 182 EOCs. Results.: Ninety-two percent of primary EOCs and 44% of EOC cell lines expressed MISIIR mRNA. We observed moderate or strong MISIIR expression via IHC in the majority of gynecologic cancers: EOC 69% (125/182), ovarian dysgerminomas 77% (17/22), endometrial cancers 75% (82/109), uterine malignant mixed Müllerian tumors (MMMT) 59% (30/51), uterine leiomyosarcomas (LMS) 52% (15/29), and endometrial stromal sarcomas (ESS) 22% (4/18). Over 74% of normal non-gynecologic tissues did not express MISIIR. There was a significant correlation between MISIIR expression and improved OS (p = 0.025, Chi square). Conclusions.: In the largest study to date, we report that MISIIR is highly expressed by a wide variety of gynecologic cancers, including cancers currently without effective systemic therapies. Low levels of expression in select non-gynecologic tissues coupled with high expression in gynecologic malignancies make MISIIR an attractive target for novel therapeutics and tumor-directed imaging in the management of gynecologic cancers. Further investigation into the impact of MISIIR expression and OS is also warranted.

Original languageEnglish (US)
Pages (from-to)141-148
Number of pages8
JournalGynecologic Oncology
Volume108
Issue number1
DOIs
StatePublished - Jan 2008

Fingerprint

Anti-Mullerian Hormone
Neoplasms
Dysgerminoma
Endometrial Neoplasms
Breast Neoplasms
Cell Line
Ovarian Neoplasms
Prostatic Neoplasms
Endometrial Stromal Sarcoma
Immunohistochemistry
Malignant Mixed Tumor
Leiomyosarcoma
Immunoblotting
Ascites
Sarcoma
Reverse Transcription
Disease-Free Survival
Interferon-gamma
Therapeutics
Ovarian epithelial cancer

Keywords

  • Endometrial cancer
  • Epithelial ovarian cancer
  • Müllerian inhibiting substance (MIS)
  • Müllerian inhibiting substance type II receptor (MISIIR)
  • Ovarian dysgerminoma
  • Uterine sarcoma

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Müllerian inhibiting substance type II receptor (MISIIR) : A novel, tissue-specific target expressed by gynecologic cancers. / Bakkum-Gamez, Jamie N; Aletti, Giovanni; Lewis, Kriste A.; Keeney, Gary; Thomas, Bijoy M.; Navarro-Teulon, Isabelle; Cliby, William Arthur.

In: Gynecologic Oncology, Vol. 108, No. 1, 01.2008, p. 141-148.

Research output: Contribution to journalArticle

@article{b1e59f553891484cbd699d9b58738e29,
title = "M{\"u}llerian inhibiting substance type II receptor (MISIIR): A novel, tissue-specific target expressed by gynecologic cancers",
abstract = "Objective.: M{\"u}llerian inhibiting substance type II receptor (MISIIR) is expressed by ovarian, breast, and prostate cancers [Masiakos PT, et al. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) Type II Receptor, bind, and are responsive to MIS. Clin Cancer Res 1999;5:3488-99; Hoshiya Y, et al. Mullerian inhibiting substance promotes interferon {gamma}-induced gene expression and apoptosis in breast cancer cells. J Biol Chem 2003;278:51703-12; Hoshiya Y, et al. Mullerian inhibiting substance induces NFkB signaling in breast and prostate cancer cells. Mol. Cell. Endocrinol. 2003;211:43-9. [1-3]]. We investigated the expression patterns of MISIIR in benign and malignant gynecologic tissues and benign non-gynecologic tissues to better assess the relevance of MISIIR as a target for new therapeutic and diagnostic approaches to gynecologic cancers. Secondarily, we examined the impact of MISIIR expression on overall survival (OS) and disease-free survival (DFS) in a cohort of epithelial ovarian cancers (EOC). Methods.: Reverse-transcription polymerase chain reaction (RT-PCR), immunoblotting, and immunohistochemistry (IHC) were used to determine MISIIR expression. EOC cell lines (10), primary EOCs (12), and tissue microarrays (TMAs) containing benign gynecologic (179) and non-gynecologic tissues (25), EOC (182), endometrial carcinomas (109), uterine sarcomas (98), and ovarian dysgerminomas (22) were examined for MISIIR expression. Clinical data were collected for a cohort of 182 EOCs. Results.: Ninety-two percent of primary EOCs and 44{\%} of EOC cell lines expressed MISIIR mRNA. We observed moderate or strong MISIIR expression via IHC in the majority of gynecologic cancers: EOC 69{\%} (125/182), ovarian dysgerminomas 77{\%} (17/22), endometrial cancers 75{\%} (82/109), uterine malignant mixed M{\"u}llerian tumors (MMMT) 59{\%} (30/51), uterine leiomyosarcomas (LMS) 52{\%} (15/29), and endometrial stromal sarcomas (ESS) 22{\%} (4/18). Over 74{\%} of normal non-gynecologic tissues did not express MISIIR. There was a significant correlation between MISIIR expression and improved OS (p = 0.025, Chi square). Conclusions.: In the largest study to date, we report that MISIIR is highly expressed by a wide variety of gynecologic cancers, including cancers currently without effective systemic therapies. Low levels of expression in select non-gynecologic tissues coupled with high expression in gynecologic malignancies make MISIIR an attractive target for novel therapeutics and tumor-directed imaging in the management of gynecologic cancers. Further investigation into the impact of MISIIR expression and OS is also warranted.",
keywords = "Endometrial cancer, Epithelial ovarian cancer, M{\"u}llerian inhibiting substance (MIS), M{\"u}llerian inhibiting substance type II receptor (MISIIR), Ovarian dysgerminoma, Uterine sarcoma",
author = "Bakkum-Gamez, {Jamie N} and Giovanni Aletti and Lewis, {Kriste A.} and Gary Keeney and Thomas, {Bijoy M.} and Isabelle Navarro-Teulon and Cliby, {William Arthur}",
year = "2008",
month = "1",
doi = "10.1016/j.ygyno.2007.09.010",
language = "English (US)",
volume = "108",
pages = "141--148",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Müllerian inhibiting substance type II receptor (MISIIR)

T2 - A novel, tissue-specific target expressed by gynecologic cancers

AU - Bakkum-Gamez, Jamie N

AU - Aletti, Giovanni

AU - Lewis, Kriste A.

AU - Keeney, Gary

AU - Thomas, Bijoy M.

AU - Navarro-Teulon, Isabelle

AU - Cliby, William Arthur

PY - 2008/1

Y1 - 2008/1

N2 - Objective.: Müllerian inhibiting substance type II receptor (MISIIR) is expressed by ovarian, breast, and prostate cancers [Masiakos PT, et al. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) Type II Receptor, bind, and are responsive to MIS. Clin Cancer Res 1999;5:3488-99; Hoshiya Y, et al. Mullerian inhibiting substance promotes interferon {gamma}-induced gene expression and apoptosis in breast cancer cells. J Biol Chem 2003;278:51703-12; Hoshiya Y, et al. Mullerian inhibiting substance induces NFkB signaling in breast and prostate cancer cells. Mol. Cell. Endocrinol. 2003;211:43-9. [1-3]]. We investigated the expression patterns of MISIIR in benign and malignant gynecologic tissues and benign non-gynecologic tissues to better assess the relevance of MISIIR as a target for new therapeutic and diagnostic approaches to gynecologic cancers. Secondarily, we examined the impact of MISIIR expression on overall survival (OS) and disease-free survival (DFS) in a cohort of epithelial ovarian cancers (EOC). Methods.: Reverse-transcription polymerase chain reaction (RT-PCR), immunoblotting, and immunohistochemistry (IHC) were used to determine MISIIR expression. EOC cell lines (10), primary EOCs (12), and tissue microarrays (TMAs) containing benign gynecologic (179) and non-gynecologic tissues (25), EOC (182), endometrial carcinomas (109), uterine sarcomas (98), and ovarian dysgerminomas (22) were examined for MISIIR expression. Clinical data were collected for a cohort of 182 EOCs. Results.: Ninety-two percent of primary EOCs and 44% of EOC cell lines expressed MISIIR mRNA. We observed moderate or strong MISIIR expression via IHC in the majority of gynecologic cancers: EOC 69% (125/182), ovarian dysgerminomas 77% (17/22), endometrial cancers 75% (82/109), uterine malignant mixed Müllerian tumors (MMMT) 59% (30/51), uterine leiomyosarcomas (LMS) 52% (15/29), and endometrial stromal sarcomas (ESS) 22% (4/18). Over 74% of normal non-gynecologic tissues did not express MISIIR. There was a significant correlation between MISIIR expression and improved OS (p = 0.025, Chi square). Conclusions.: In the largest study to date, we report that MISIIR is highly expressed by a wide variety of gynecologic cancers, including cancers currently without effective systemic therapies. Low levels of expression in select non-gynecologic tissues coupled with high expression in gynecologic malignancies make MISIIR an attractive target for novel therapeutics and tumor-directed imaging in the management of gynecologic cancers. Further investigation into the impact of MISIIR expression and OS is also warranted.

AB - Objective.: Müllerian inhibiting substance type II receptor (MISIIR) is expressed by ovarian, breast, and prostate cancers [Masiakos PT, et al. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) Type II Receptor, bind, and are responsive to MIS. Clin Cancer Res 1999;5:3488-99; Hoshiya Y, et al. Mullerian inhibiting substance promotes interferon {gamma}-induced gene expression and apoptosis in breast cancer cells. J Biol Chem 2003;278:51703-12; Hoshiya Y, et al. Mullerian inhibiting substance induces NFkB signaling in breast and prostate cancer cells. Mol. Cell. Endocrinol. 2003;211:43-9. [1-3]]. We investigated the expression patterns of MISIIR in benign and malignant gynecologic tissues and benign non-gynecologic tissues to better assess the relevance of MISIIR as a target for new therapeutic and diagnostic approaches to gynecologic cancers. Secondarily, we examined the impact of MISIIR expression on overall survival (OS) and disease-free survival (DFS) in a cohort of epithelial ovarian cancers (EOC). Methods.: Reverse-transcription polymerase chain reaction (RT-PCR), immunoblotting, and immunohistochemistry (IHC) were used to determine MISIIR expression. EOC cell lines (10), primary EOCs (12), and tissue microarrays (TMAs) containing benign gynecologic (179) and non-gynecologic tissues (25), EOC (182), endometrial carcinomas (109), uterine sarcomas (98), and ovarian dysgerminomas (22) were examined for MISIIR expression. Clinical data were collected for a cohort of 182 EOCs. Results.: Ninety-two percent of primary EOCs and 44% of EOC cell lines expressed MISIIR mRNA. We observed moderate or strong MISIIR expression via IHC in the majority of gynecologic cancers: EOC 69% (125/182), ovarian dysgerminomas 77% (17/22), endometrial cancers 75% (82/109), uterine malignant mixed Müllerian tumors (MMMT) 59% (30/51), uterine leiomyosarcomas (LMS) 52% (15/29), and endometrial stromal sarcomas (ESS) 22% (4/18). Over 74% of normal non-gynecologic tissues did not express MISIIR. There was a significant correlation between MISIIR expression and improved OS (p = 0.025, Chi square). Conclusions.: In the largest study to date, we report that MISIIR is highly expressed by a wide variety of gynecologic cancers, including cancers currently without effective systemic therapies. Low levels of expression in select non-gynecologic tissues coupled with high expression in gynecologic malignancies make MISIIR an attractive target for novel therapeutics and tumor-directed imaging in the management of gynecologic cancers. Further investigation into the impact of MISIIR expression and OS is also warranted.

KW - Endometrial cancer

KW - Epithelial ovarian cancer

KW - Müllerian inhibiting substance (MIS)

KW - Müllerian inhibiting substance type II receptor (MISIIR)

KW - Ovarian dysgerminoma

KW - Uterine sarcoma

UR - http://www.scopus.com/inward/record.url?scp=37449021993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37449021993&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2007.09.010

DO - 10.1016/j.ygyno.2007.09.010

M3 - Article

C2 - 17988723

AN - SCOPUS:37449021993

VL - 108

SP - 141

EP - 148

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -